Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine; and AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine, as well as AEB4104, an engineered human enzyme that targets the reduction of elevated levels of the amino acid homocysteine. Aeglea BioTherapeutics, Inc. has a clinical collaboration agreement with Merck to evaluate the combination of pegzilarginase with Merck's anti-PD1 therapy, pembrolizumab, for the treatment of patients with small cell lung cancer. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone512-942-2935
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.20 million
Profitability
Miscellaneous
Employees43
Next Earnings Date3/12/2019 (Estimated)
OptionableOptionable
Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions
What is Aeglea Bio Therapeutics' stock symbol?
Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE."
How were Aeglea Bio Therapeutics' earnings last quarter?
Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) posted its earnings results on Thursday, November, 8th. The biotechnology company reported ($0.54) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.10. Aeglea Bio Therapeutics had a negative return on equity of 62.12% and a negative net margin of 480.92%. View Aeglea Bio Therapeutics' Earnings History.
When is Aeglea Bio Therapeutics' next earnings date?
What price target have analysts set for AGLE?
4 brokers have issued 12-month price objectives for Aeglea Bio Therapeutics' stock. Their forecasts range from $20.00 to $37.00. On average, they anticipate Aeglea Bio Therapeutics' share price to reach $26.00 in the next twelve months. This suggests a possible upside of 215.2% from the stock's current price. View Analyst Price Targets for Aeglea Bio Therapeutics.
What is the consensus analysts' recommendation for Aeglea Bio Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea Bio Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aeglea Bio Therapeutics.
Has Aeglea Bio Therapeutics been receiving favorable news coverage?
Media coverage about AGLE stock has trended somewhat positive on Saturday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aeglea Bio Therapeutics earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Aeglea Bio Therapeutics' key competitors?
Some companies that are related to Aeglea Bio Therapeutics include Apellis Pharmaceuticals (APLS), Y-mAbs Therapeutics (YMAB), Inflarx (IFRX), G1 Therapeutics (GTHX), Vectura Group (VEGPF), Intra-Cellular Therapies (ITCI), ANI Pharmaceuticals (ANIP), Arvinas (ARVN), Principia Biopharma (PRNB), Evolus (EOLS), Omeros (OMER), Eagle Pharmaceuticals (EGRX), CymaBay Therapeutics (CBAY), Dicerna Pharmaceuticals (DRNA) and Dynavax Technologies (DVAX).
What other stocks do shareholders of Aeglea Bio Therapeutics own?
Who are Aeglea Bio Therapeutics' key executives?
Aeglea Bio Therapeutics' management team includes the folowing people:
- Dr. Anthony G. Quinn M.B Ch.B., Ph.D., FRCP, Pres, CEO & Director (Age 57)
- Mr. Charles N. York II, CFO & VP (Age 42)
- Dr. James E. Wooldridge M.D., Chief Medical Officer (Age 53)
- Dr. Leslie Sloan Ph.D., Sr. VP of Operations
- Mr. Eugene Sackett, VP of HR
When did Aeglea Bio Therapeutics IPO?
(AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.
Who are Aeglea Bio Therapeutics' major shareholders?
Aeglea Bio Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (5.64%), BlackRock Inc. (5.44%), Aisling Capital Management LP (3.63%), Sphera Funds Management LTD. (2.50%), Comprehensive Portfolio Management LLC (1.21%) and Dimensional Fund Advisors LP (1.19%). Company insiders that own Aeglea Bio Therapeutics stock include Aaron Schuchart, Anthony G Quinn, Bioventures Ltd Novartis and Charles N York II. View Institutional Ownership Trends for Aeglea Bio Therapeutics.
Which institutional investors are selling Aeglea Bio Therapeutics stock?
AGLE stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Sphera Funds Management LTD., Deltec Asset Management LLC, Squarepoint Ops LLC and Bank of Montreal Can. Company insiders that have sold Aeglea Bio Therapeutics company stock in the last year include Aaron Schuchart and Bioventures Ltd Novartis. View Insider Buying and Selling for Aeglea Bio Therapeutics.
Which institutional investors are buying Aeglea Bio Therapeutics stock?
AGLE stock was acquired by a variety of institutional investors in the last quarter, including Aisling Capital Management LP, Comprehensive Portfolio Management LLC, BlackRock Inc., Dimensional Fund Advisors LP, Fosun International Ltd, Algert Global LLC, Millennium Management LLC and Bank of America Corp DE. Company insiders that have bought Aeglea Bio Therapeutics stock in the last two years include Anthony G Quinn and Charles N York II. View Insider Buying and Selling for Aeglea Bio Therapeutics.
How do I buy shares of Aeglea Bio Therapeutics?
Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aeglea Bio Therapeutics' stock price today?
One share of AGLE stock can currently be purchased for approximately $8.25.
How big of a company is Aeglea Bio Therapeutics?
Aeglea Bio Therapeutics has a market capitalization of $197.69 million and generates $5.20 million in revenue each year. The biotechnology company earns $-27,230,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Aeglea Bio Therapeutics employs 43 workers across the globe.
What is Aeglea Bio Therapeutics' official website?
How can I contact Aeglea Bio Therapeutics?
Aeglea Bio Therapeutics' mailing address is 901 SOUTH MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE SUITE 250, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]
MarketBeat Community Rating for Aeglea Bio Therapeutics (NASDAQ AGLE)
MarketBeat's community ratings are surveys of what our community members think about Aeglea Bio Therapeutics and other stocks. Vote "Outperform" if you believe AGLE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGLE will underperform the S&P 500 over the long term. You may vote once every thirty days.
